This, in turn, could decrease the true number of drugs open to consumers. What do you consider can be carried out to provide consumers with reasonably priced drugs and keep money flowing to R&D simultaneously? Photo by klynslis.. Tuesday Last, a US House of Representatives subcommittee held a hearing in the deals pharmaceutical companies strike with each other to delay generic drugs from reaching the marketplace. In these deals, a company desperate to continue making a benefit from its brand-name medication pays another firm to avoid selling a generic edition.With longer follow-up available now, responses seem to be durable. Out of 12 major cytogenetic responses in patients with chronic stage CML, 11 remain on therapy without progression after typically almost a year on treatment . Nine of the 12 sufferers had cytogenetic response verified with at least a second assessment after three months. Only one individual experienced CML progression after having attained a MCyR which was in a patient enrolled in the sub-therapeutic 4 mg dose cohort.